Entera
entera.ai
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Entera is the AI-powered SaaS and Services platform helping single-family real estate investors buy, sell, and operate homes at scale.
News
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Read more
Report
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tabl...
Read more
Report
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P.Expected gross proceeds are anticipated to extend the Company
Read more
Report
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.